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Purpose: The efficacy of octreotide in the treatment of acute pancreatitis is controversial. Octreotide treatment for acute pan-
creatitis often shows poor correlation between results obtained in experimental studies and results of clinical trials. In a clin-
ical setting, there is always a delay between the onset of the disease and initiation of the octreotide treatment. The aim of this 
study is to investigate the relationship between the beginning of treatment and alteration in effectiveness of octreotide. 
Methods: Acute pancreatitis was induced by pancreatic duct ligation in 50 rats. The rats were randomly divided into five 
groups. Octreotide was not used in group 1 (control group). Only single dose (4 μg/kg) octreotide was administered subcuta-
neously to rats in group 2, having induced pancreatitis. Octreotide treatment was begun at different times (8th, 24th, 48th 
hour) in three other groups and continued treatment at a dosage of 4 μg/kg t.i.d. The animals were sacrificed at the end of the 
72nd hour and blood and tissue samples were collected. Results: Leukocyte count and plasma amylase values were less in 
groups 2 and 3. Hemorrhagic focuses were encountered less at pancreas tissues in group 3. Pancreatic necrosis and alveolar 
capillary basal membrane damage were lower in groups 3 and 4. No difference was found in fasting blood glucose, calcium 
and hematocrit. Conclusion: Octreotide had benefical effects in acute pancreatitis when octreotide treatment was begun in 
the first 24 hours.
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INTRODUCTION
Treatment and prognosis of acute pancreatitis remain a 
common problem. Acute pancreatitis induced with vari-
ous etiologic factors can be recovered from with insignif-
icant symptoms or could progress to severe clinical con-
ditions and, eventually, death [1-5]. Although several 
treatment protocols have been suggested, their benefits 
are still limited.
In the early 1980’s, with experimental studies con-
ducted, it was supposed that somatostatin and analogues 
could be used for acute pancreatitis treatment [6,7]. These 
pharmacologic agents were evaluated in several clinical 
and experimental studies but contradictory results were Octreotide and treatment of pancreatitis
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found [8,9]. Nowadays, while some researchers support 
the idea that somatostatin and its analogues are effective 
for the treatment of acute pancreatitis [10-12], some of the 
clinicians emphasize that these agents have no beneficial 
effects in acute pancreatitis treatment [13-15].
Multiple therapeutic modalities studied for acute pan-
creatitis often show a poor correlation between results ob-
tained in experimental studies and results of clinical trials. 
One of the main reasons for this discrepancy is that in most 
experimental studies the drugs were administered imme-
diately after induction of pancreatitis, whereas in the clin-
ical setting, there is almost always a delay between the on-
set of the disease and initiation of the treatment.
Although octreotide, a semisynthetic analogue of soma-
tostatin, has been extensively used in clinical practice and 
experimental studies, as far as we know there are few 
studies in the literature demonstrating a relation between 
beginning time of treatment and alteration of effectiveness 
of equal doses octreotide.
This experimental study was conducted to evaluate the 
alteration of effectiveness of octreotide in experimentally 
induced pancreatitis beginning treatment with octreotide 
at different times.
METHODS
Median incisions were performed in 50 Sprague- 
Dawley rats of both sexes with a body weight of 250 to 300 
g. Anaesthesia was induced by intramuscular injection of 
ketamine HCI (25 mg/kg). Acute pancreatitis was induced 
by pancreatic duct ligation in 50 rats. The rats were ran-
domly divided into five groups of 10 rats each, as follows: 
Group 1 (n = 10), octreotide was not used.
Group 2 (n = 10), single dose octreotide was admini-
stered subcutaneously to the rats immediately after pan-
creatic duct ligation at a dosage of 4 μg/kg.
Group 3 (n = 10), initial dose of octreotide was ad-
ministered subcutaneously to the rats at the 8th hour and 
continued treatment at a dosage of 4 μg/kg t.i.d.
Group 4 (n = 10), initial dose of octreotide was ad-
ministered subcutaneously to the rats at the 24th hour and 
continued treatment at a dosage of 4 μg/kg t.i.d.
Group 5 (n = 10), initial dose of octreotide was ad-
ministered subcutaneously to the rats at the 48th hour and 
continued treatment at a dosage of 4 μg/kg t.i.d.
The animals were allowed to have water and a standard 
rat diet when they awoke. The rats were sacrificed at the 
end of the 72nd hour. Blood samples (5 mL) were with-
drawn from the hearth and 1 g tissue samples were taken 
from pancreas and lung. 
Haematological and biochemical parameters were 
measured in Olympus AV-2700 (Olympus Co., Tokyo, 
Japan) and Coulter STKS (Beckman Coulter Inc., Brea, CA, 
USA). Tissue samples were fixed in a 10% formaldehyde 
solution. The tissue sections were stained with haematox-
ylin-eosin and examined by a pathologist who was un-
aware of treatment and test groups. Histopatologic 
changes were graded from 0 to 3 points and having added 
these points, the total score of every group was found and 
the mean was calculated (0, absent; 1, mild; 2, moderate; 3, 
severe). Histopathologic changes in the pancreas were 
evaluated for presence and degree of interstitial edema, 
neutrophil infiltration, haemorrhagia and necrosis. The 
presence and degree of interstitial edema, neutrophil in-
filtration and damage in alveolar capillary membrane 
were used for evaluation of lung tissue.
SPSS ver. 14.0 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis. The haematological and biochemical 
parameters were expressed as mean ± SD. Statistical com-
parisons of the data expressed as mean ± SD were ana-
lyzed by Mann-Whitney U test. The chi-squared test was 
used for the analysis of histopathological parameters. 
Statistical significance was set at P ＜  0.05. 
RESULTS
There was no death during the experimental study. 
Leukocyte count was lower in groups 2 and 3 than the oth-
er groups (P ＜  0.05). Plasma amylase values increased in 
all groups. This increase was significantly low in groups 2 
and 3 (Fig. 1A). A significant difference was not observed 
in fasting blood glucose, calcium and hematocrit (Table 1).M. Ertugrul Kafali, et al.
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Fig. 1. Amylase levels and degree of histopathological changes that were found to differ between groups. Error bars denote Standard 
deviation (SD). (A) Amylase levels. (B) Pancreatic haemorrhagia. (C) Pancreatic necrosis. (D)  Alveolar capillary basal membrane damage.
Parameter Group 1 Group 2 Group 3 Group 4 Group 5
White blood cell 9,420 ± 273   6,620 ± 161
a)     7,260 ± 190
a)    9,400 ± 287   8,870 ± 308
Hematocrit  39 ± 5 40 ± 3   37 ± 2    39 ± 3   38 ± 5
Glucose  96 ± 8 89 ± 6   103 ± 11  105 ± 9   96 ± 4
Amylase 3,494 ± 154 1,790 ± 62
a)  1,681 ± 93
a) 2,756 ± 22 2,194 ± 85
Ca
2+ 8,9 ± 1 9,5 ± 1     9 ± 1  10,3 ± 1   10 ± 0
Values are presented as mean ± SD.
a)P ＜  0.05, groups 2 and 3 vs. others.
Table 1. The levels of hematologic and biochemical parameters
Histopathological changes in the pancreas 
Hemorrhagic focuses were less in group 3 than the other 
groups (Fig. 1B). Pancreatic necrosis in pathological ex-
amination was encountered less in groups 3 and 4 (Fig. 
1C). There was no statistical difference for interstitial ede-
ma and neutrophil infiltration among all the groups (Table 
2).
Histopathological changes in the lung 
Alveolar capillary basal membrane damage was lower 
in groups 3 and 4 than the other groups (Fig. 1D). There 
was no statistical difference among the groups for edema 
and neutrophil infiltration in pathological examination of 
lung (Table 3).Octreotide and treatment of pancreatitis
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G r o u p  1G r o u p  2G r o u p  3G r o u p  4G r o u p  5
Edema   2.5 ± 0.4 2.2 ± 0.6 2.1 ± 0.3 2.4 ± 0.5 2.2 ± 0.3
Neutrophil infiltration 2.2 ± 0.3 2.4 ± 0.5 2.0 ± 0.9 2.2 ± 0.6 2.5 ± 0.4
Haemorrhage  1.9 ± 0.4 2.0 ± 0.8  1.3 ± 0.7
a) 1.6 ± 0.3 2.1 ± 0.7
Necrosis  2.0 ± 0.4 1.9 ± 0.2  1.4 ± 0.2
b)  1.3 ± 0.4
b) 1.8 ± 0.4
Values are presented as mean ± SD.
a)P ＜  0.05, group 3 vs. others. 
b)P ＜  0.05, group 3 and 4 vs. others.
Table 2. The degree of histopathological changes in the pancreas
Group 1 Group 2 Group 3 Group 4 Group 5
Edema  2.2 ± 0.5 2.1 ± 0.4 2.1 ± 0.5 1.7 ± 0.6 2.0 ± 0.5
Neutrophil infiltration 2.4 ± 0.4 2.5 ± 0.3 2.2 ± 0.7 1.9 ± 0.4 2.4 ± 0.6
Alveolar-capillary membrane damage 1.8 ± 0.2 1.7 ± 0.3  1.2 ± 0.6
a)  1.5 ± 0.2
a) 1.5 ± 0.4
Values are presented as mean ± SD.
a)P ＜  0.05, group 3 and 4 vs. others.
Table 3. The degree of histopathological changes in the lungs
DISCUSSION
Acute pancreatitis is still a serious diagnostic and ther-
apeutic problem. Acute pancreatitis can present in a wide 
clinical spectrum ranging from a mild, self-limiting lo-
calized disease to a fatal, widespread multi-organ failure 
in which mortality ranges from 14 to 30% [16,17]. Clinical 
features together with elevation of plasma concentrations 
of pancreatic enzymes are cornerstones of diagnosis. In 
spite of many experiments, there are no satisfactory meth-
ods of the treatment in clinical practice. The major prob-
lem is the lack of specific drugs, especially in the early 
phase of the disease. The initiating pathophysiological 
process is not known, but autodigestion by pancreatic en-
zymes may be responsible for disease progression [4]. The 
main disorder of this disease is necrosis of the pancreatic 
gland. 
Octreotide has a profound inhibitory effect on the endo-
crine and exocrine secretions of the pancreas, stomach and 
small intestine [18]. In recent years, a huge number of ar-
ticles have been published on the treatment of acute pan-
creatitis in experimental models. However, it is difficult to 
translate these results into clinical practice. Controversial 
results are present in clinical studies on the effect of octreo-
tide in the treatment of patients with acute pancreatitis 
[10,11,13]. In most experimental studies, octreotide was 
administered immediately after induction of pancreatitis, 
but in clinical settings there is always a delay between the 
onset of the disease and initiation of the octreotide 
treatment. Uhl et al. [13] conducted a randomised, double 
blind, multicentre trial to look into the efficacy of 
octreotide. On the basis of this trial, they claimed that oc-
treotide treatment for acute pancreatitis can not be 
recommended. That the median time elapsing from the 
onset of symptoms to entry into the study was 44 hours 
(range, 0 to 145 hours) is a salient point in their study. This 
inference is totally unacceptable for now. 
The question to be answered is - what is the deadline to be-
gin acute pancreatitis treatment for octreotide to be effective? 
There are two studies in the literature partially trying to 
evaluate this subject.
Kaplan et al. [19] studied the effects of delayed treat-
ment with octreotide on acute experimental pancreatitis. 
They started octreotide treatment either 4 or 12 hours after 
onset. The rats were sacrificed at the end of the 36th hour 
in this study. The authors have not observed any effect of 
octreotide on amylase levels. They report that octreotide 
ameliorated pancreatic edema and histopathological in-
jury score. In their study, the deadline to begin octreotide 
treatment is 12 hours, but sometimes octreotide treatment 
could begin later; from the onset of the disease in clinical 
conditions. Octreotide treatment was begun at different M. Ertugrul Kafali, et al.
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times in our study (0, 8, 24, 48 hours after the operation).
The deadline to begin octreotide treatment is 24 hours in 
a study by Chen et al. [20]. In this study they used octreo-
tide at different doses in different groups. For this reason, 
it is difficult to evaluate the alteration of effectiveness of 
octreotide that was begun at different times.
 In many experimental studies, giving octreotide imme-
diately after induction of pancreatitis showed benefical ef-
fects on both histopathological and biochemical parame-
ters in experimental pancreatitis. Less pancreatic edema, 
necrosis and inflammatory cell infiltration, reduction in 
serum amylase were put forward by these studies [21,22].
In our study plasma amylase levels and leukocyte count 
were less in groups 2 and 3. Octreotide ameliorated pan-
creatic necrosis and alveolar capillary basal membrane 
damage in groups 3 and 4. Control group and group 5 
were found to be similar for plasma amylase levels and 
histopathological damage in pancreas and lung tissues.
In the advanced pancreatitis case; the fact that there ex-
ists no benefical effects on inhibition of pancreatic en-
zymes is obvious as inflamation diffused, permeability in-
creased and necrosis developed. In this case, octreotide is 
not effective on the course of disease. On the basis of our 
results we think that if pancreatic enzymes are inactivated 
at the early phase of pancreatitis without damaging pan-
creas tissue and other organs via systemic circulation; oc-
treotide treatment can be useful.
In conclusion, octreotide had benefical effects on histo-
pathological injury in induced acute pancreatitis by pan-
creatic duct ligation, when octreotide treatment was be-
gun in the first 24 hours.
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